Anti-human B7-H4 antibodies and their uses

US9574000B2 · kind B2 · utility

Assignees

• MedImmune Limited · US
• THE JOHNS HOPKINS UNIVERSITY · US

Inventors

• Solomon Langermann · Baltimore, US
• Linda Liu · Clarksville, US
• Sheng Yao · Columbia, US
• Lieping Chen · Hamden, US
• Michael Glen Overstreet · Gaithersburg, US

Key dates

• Filing date: Dec 19, 2013
• Grant date: Feb 21, 2017
• Expiry date: Dec 19, 2033

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/92
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Anti-human B7-H4 antibody “6H3”, antigen-binding fragments, derivatives, and humanized variants thereof that are capable of immunospecifically binding to B7-H4, and the uses of such molecules in the diagnosis and the treatment of cancer and other diseases are disclosed. In preferred embodiments, the molecules are used to retard or prevent tumor growth, inhibit tumor-mediated suppression, eliminate tumors and/or deplete or block the activity of tumor-associated macrophages (“TAMs”) so as to alter their activity and/or decrease TAM-mediated immune suppression.